Demographic and Clinical Patient Data
| Variable | Control (n = 56) | ADT (n = 56) | P |
|---|---|---|---|
| Age (y) | 69.6 (±7.2) | 70.4 (±8.0) | 0.58 |
| Weight (kg) | 86.2 (±12.6) | 83.4 (±13.6) | 0.31 |
| Tracer dose (MBq) | 181.8 (±18.1) | 183.4 (±19.4) | 0.59 |
| PSA (μg/dL)* | 13.0 (±46.1) | 7.1 (±12.6) | 0.06 |
| GFR (mL/min)† | 78.4 (±15.5) | 81.0 (±14.2) | 0.39 |
| MTV (cm3) | 3.3 (±5.3) | 5.0 (±6.2) | 0.20 |
| PSMA-positive lesions | |||
| Prostate | 21 (37.5%) | 21 (37.5%) | >0.99 |
| Lymph nodes | 19 (33.9%) | 14 (25.0%) | 0.41 |
| Bone | 8 (14.3%) | 18 (32.1%) | 0.04 |
| Viscera (lung) | 2 (3.6%) | 1 (1.8%) | >0.99 |
| Mean lesional SUVmean | |||
| Prostate | 13.1 (±11.4) | 10.8 (±8.4) | 0.43 |
| Lymph nodes | 7.5 (±4.3) | 10.39 (±6.3) | 0.13 |
| Bone | 4.9 (±2.2) | 9.4 (±12.5) | 0.84 |
| Viscera (lung) | 4.79 (4.0–5.6) | 7.7 | —‡ |
| Mean ADT runtime (m) | — | 24.0 ± 34.9 | |
| Runtimes binned (m) | |||
| 1–6 | — | 15 (26.8%) | |
| >6 | — | 41 (73.2%) | |
| ADT drug class | |||
| GnRH analog | |||
| Leuprorelin | — | 38 (67.9%) | |
| Triptorelin | — | 2 (3.6%) | |
| GnRH antagonist | |||
| Degarelix | — | 16 (28.6%) | |
| Previous cytotoxic treatments | 20 (35.7%) | ||
| CHT | — | 19 (33.9%) | |
| 177Lu-PSMA | — | 3 (5.3%) |
↵* Missing data for control (n = 8) and ADT group (n = 4).
↵† Missing data for control (n = 9) and ADT group (n = 8).
↵‡ Statistical testing not feasible because of sample size in control group (n = 2; data as mean and range) and ADT group (n = 1).
PSA = prostate-specific antigen; GFR = glomerular filtration rate; GnRH = gonadotropin-releasing hormone; CHT = chemotherapy.
Qualitative data are number and percentages; continuous data are mean and SD.